The National Institute for Health and Care Excellence (Nice)
-
Low-risk pregnant women urged to avoid hospital birthsNHS guidance from National Institute for Health and Care Excellence suggests 45% of births ‘unsuitable’ for labour wards -
Hospital births have never been safest – Nice is right to reverse this mythSince the 1960s, UK births have increasingly taken place in the stressful environment of hospitals, but as this week’s guidelines highlight, there was never any proof that this was the safer option
-
Tripling weight loss surgeries would cut type 2 diabetes treatment billUp to two million people could be eligible, though it is not seen as a long-term solution for obesity
-
Pill that helps reduce desire to drink alcohol available on prescriptionClinical watchdog Nice says patients can request nalmefene alongside counselling support to cut down drinking
-
Costly cancer drugs may be cut from special funding listReassessment of dozens of medicines, including Kadcyla and Avastin, follows overspending of the £600m Cancer Drugs Fund
-
Should schools be responsible for children's dental health?
The advisory body Nice has suggested that nurseries and primary schools could have a role in children's teeth-brushing and oral hygiene. With half of five-year-olds having decay or fillings in some parts of England, should schools step in?
-
Cannabis drug for multiple sclerosis ‘too costly’ for England but not WalesNice says price set by manufacturer of Sativex is too high for the benefit it gives MS patients
-
Breast cancer drug Perjeta could extend patients’ lives by 15 months – studyDrugmaker Roche says £43,000-a-year treatment can extend lives of women with aggressive form of disease
-
Skin cancer drug should be available on NHS, officials say
Nice suggests patients should have access to dabrafenib if makers GSK give the health service a discount
-
Service users and carers help draw up homecare blueprint
Service users and carers help draw up homecare blueprint
Bridget Warr, chief executive, UK Homecare AssociationPractitioners, carers and service users are helping the National Institute for Health and Care Excellence write guidance for improving homecare
-
How the NHS can deal with soaring drugs pricesNational Insitute of Clinical Excellence decisions have sparked debate over funding the spiralling cost of medication, writes Andrew Apps
-
Nice decision on prostate cancer drug is a 'kick in the teeth' for patientsCharity and scientists criticise drug approval body for not offering abiraterone to sufferers until after chemotherapy
-
The Guardian view on the NHS and soaring drugs pricesEditorial: The cancer drugs fund has become a way of escaping the constraints carefully established by Nice
-
Breast cancer drug Kadcyla deemed 'too expensive' for NHS - video
The National Institute for Health and Care Excellence is too expensive for use on the NHS but Roche says it has already been picked up elsewhere
-
-
Cancer Drugs Fund seems to help pharmaceuticals giant Roche most
As Nice rejects breast cancer drug Kadcyla over cost, how Swiss firm has benefited from fund it played key role in establishing
-
Drugs watchdog condemns Roche for high price of breast cancer therapy
Regulator Nice unable to approve £90,000 drug exceeding NHS limit, but pharmaceuticals firm calls UK funding system 'broken'
-
British Medical Journal acted correctly in controversy over statinsArticles containing mistaken fears over side effects of heart drugs did not need to be retracted, says independent panel
-
-
Statins guidance to GPs is a victory for vested interests over evidenceKailash Chand: Nice’s advice is based on drug-company-sponsored trials. People at low risk of heart attacks are better off walking more and eating less processed food
-
NHS medicines watchdog lowers bar for statins prescriptions
An estimated 4.5 million more people will be eligible for statins under new guidance, in addition to 13 million already eligible
-
Hospital red flag events should prompt staffing action, says Nice
Lack of patient checks or delays in issuing pain relief will act as trigger for considering increasing staff numbers
-
Should the NHS lower its gastric band surgery threshold?
Stomach-reducing surgery to restrict eating could be offered to an additional 800,000 people under new NHS guidelines. Good idea? Vote in our poll
-
-
NHS anti-obesity plans could lead to sharp rise in gastric band surgery
Threshold for bariatric operations could be lowered to help with soaring number of cases of type 2 diabetes
-
Sharing bed with baby in first year may raise risk of sudden infant death
Parents should avoid co-sleeping with infants during the first 12 months to avoid Sids, says national health institute
-
-
Doctors advised against aspirin for patients with irregular heart rhythm
Experts at Nice say using anticoagulants, not antiplatelets like aspirin, could avert 7,000 strokes and 2,000 deaths a year
-
Professor who sparked statins row says government should interveneProf Sir Rory Collins says he has little confidence in British Medical Journal's inquiry into papers on side-effects of drugs
-
Statins for people at low risk of heart disease needs rethink, say top doctors
Nice guidelines will 'medicalise' five million healthy people, says letter signed by Royal College of Physicians chief among others
-
GPs urged to send obese and overweight to slimming classes
Overweight people told losing just 3% and keeping it off can have significant beneficial effects in new NHS guidance
-
Calls for millions to be given free vitamin D supplements
One in five adults at risk of deficiency, with a lack of the 'sunshine' vitamin linked to soft bones and other conditions
-
Hospitals need thousands of extra nurses 'or patients' safety will be at risk'New NHS guidelines from Nice propose maximum of eight patients to one nurse to prevent dangerous understaffing
-
Big pharma's ransom for new drugsLetters: I agree you can't put a price tag on a terminally ill person's remaining months. But with Kadcyla's £90,000 price tag, hasn't Roche done just that?
-
Deborah Orr: The NHS watchdog, Nice, is being portayed as penny-pinching over its refusal to fund a hugely expensive new cancer drug. But shouldn't we be asking why its manufacturers want to charge so much?
Breast cancer drug Kadcyla is too expensive for the NHS – not to pay for it is the correct decision -
-
The real reason drugs cost so much – and why big pharma is so richMolly Scott Cato: The lack of a free market makes drugs very expensive, and increasing market consolidation will exacerbate the problem
-
Breast cancer drug turned down for NHS use due to high cost
Decision on Herceptin-style drug which costs £90,000 but can prolong lives by nearly six months heavily criticised
-
Patients with end-stage liver disease caused by hepatitis C to get new drug
NHS will pay for about 500 people to receive Sofosbuvir, which could cure them, without waiting for guidance from Nice
-
Of course children need limits on their screen time – but how to enforce it?